You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II

    SBC: RaeSedo, LLC            Topic: NHLBI

    Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  2. The Sustainable Heartland Accelerator Regional Partnership (SHARP) Hub

    SBC: BBC ENTREPRENEURIAL TRAINING & CONSULTING LLC            Topic: 500

    Project Summary/Abstract Despite the investment of billions of dollars in biomedical research each year from NIH, barriers remain in effectively translating basic science discoveries from academia to commercial products that benefit patients. These barriers include a funding gap between basic research and commercial developments, a lack of knowledge by innovators on how to bring products to market ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    Summary: The ultimate goal of this Phase II application is to develop novel small molecule, broad-spectrum therapeutics against viral infections caused by filoviruses, arenaviruses, and other viruses that depend on the PPxY L-domain motif for egress and spread of infection. Some of these viruses, including Ebola (EBOV), Marburg (MARV), and Lassa fever (LAFV) viruses, are highly pathogenic and clas ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human Pa

    SBC: NANOVIR, LLC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The proposal seeks support for the pre-clinical development of broad spectrum compounds for treatment of human papillomavirus (HPV). HPV, the most common sexually-transmitted virus, is the cause of cervical dysplasia and cervical cancer. It has also been implicated in several other hyperproliferative diseases, such as cancers of the mouth and anus, as well as t ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Catheter Based Cardiovascular Device Retrieval System

    SBC: Onocor LLC            Topic: NHLBI

    Recent advances in technology have made possible the treatment of a growing number of structural cardiovascular diseases by catheter based procedures. Atrial septal defects (ASD), ventricular septal defects (VSD), aortic aneurysm, congenital defects and valve disease are all currently being treated with catheter based strategies. These procedures are complex and are prone to device misplacement, e ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. IND enabling development of LGM2605 as adjuvant treatment for asthma

    SBC: Lignamed, LLC            Topic: NIAID

    Project summary IND enabling development of LGM2605 as adjuvant treatment for asthma Glucocorticoid resistance is a major treatment problem in asthma. Our recent studies in mice, non-human primates and severe asthma patients, along with reports by others suggest that glucocorticoid receptor (GR) expression was impaired by psychosocial stress, in association with enhanced NF-kB activation and gluco ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Pre-Clinical HPV16 Antiviral Compound Development

    SBC: NANOVIR, LLC.            Topic: N/A

    Location NANOVIR, LLC. 4717 CAMPUS DR, STE 1300 KALAMAZOO, MI 49008 United States 2R42AI062182-03A1 $2 942 780.00 2 008 Pre-Clinical HPV16 Antiviral Compound Development Department of Health and Human Services National Institutes of Health STTR N N N PHS2 ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Omniphobic Cerebral Shunt to Eliminate Clogging and Dysfunction

    SBC: FREEFLOW MEDICAL DEVICES LLC            Topic: 106

    PROJECT SUMMARY Hydrocephalus causes long term neurological problems and patient suffering. Current treatments, most of which involve surgical diversion of cerebrospinal fluid (CSF) with shunt catheters, fail at an alarming rate. Approximately 98% of all shunts fail within 10 years, and this failure rate is the dominant contributor to the $2 billion-per-year cost that hydrocephalus incurs on our h ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate

    SBC: NeuroKine Therapeutics, LLC            Topic: NIA

    ABSTRACT Alzheimer’s disease (AD) and related dementias are increasing rapidly yet, remarkably, there are no approved disease modifying drugs. Virtually all trials targeting amyloid related pathways have failed over the last 10 years. Regrettably, few alternative targets or pathways have been explored. Therefore, there is an urgent need to explore alternative pathways as monotherapies or as cons ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. A novel vaccine: botulinum neurotoxin subunit on a viral carrier.

    SBC: MOLECULAR TARGETING TECHNOLOGIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): According to the NIAID fact sheet on Botulism, the extreme toxicity of botulinum neurotoxins (BoNT) and the ease of production, transport, and delivery make this an agent of extreme bioterrorism concern. Nonetheless, although there are major vaccine development initiatives ongoing, there currently is no approved Botulinum toxin vaccine available. Advances i ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government